Recombinant ERG / ETS Transcription Factor (Prostate Cancer Marker) Antibody [ERG/22R]

• Transcriptional regulator. May participate in transcriptional regulation through the recruitment of SETDB1 histone methyltransferase and subsequent modification of local chromatin structure.

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.Storage and StabilityAntibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

This antibody is available for research use only and is not approved for use in diagnosis.

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.Storage and StabilityAntibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.Known Applications &Suggested DilutionsImmunohistochemistry (Formalin-fixed) (1-2ug/ml for 30 minutes at RT)(Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95 °C followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.Specificity & CommentsERG (ETS-related gene) is a proto-oncogene, a member of the ETS family of transcription factors. The ERG gene encodes for a nuclear protein, also called ERG, which is involved in hematopoietic and endothelial development. ERG remains constitually expressed in endothelial cells in blood and lymphatic vessels, and in bone marrow stem cells. ERG is expressed in virtually all endothelial neoplasms including hemangioendothelioma, angiosarcoma and Kaposi sarcoma. ERG is overexpressed secondary to gene rearrangement in cases of prostate adenocarcinoma, gastrointestinal stromal tumor, synovial sarcoma, meningioma, epithelioid sarcoma, malignant rhabdoid tumor, acute myeloid leukemia and blastic extramedullary myeloid tumor, and rarely Ewing sarcoma / primitive peripheral neuroectodermal tumor, chondrosarcoma, osteosarcoma, and rhabdomyosarcoma. For the identification of endothelial differentiation ERG seems more sensitive and specific than any other marker. Moreover, the interpretation is often easier due to the nuclear reaction, which also allows for double stains with cytoplasmic markers like podoplanin. Among carcinomas, ERG is highly specific for prostate, while the sensitivity is moderate.LimitationsThis antibody is available for research use only and is not approved for use in diagnosis.WarrantyThere are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.Key ReferencesMiettinen M. Histopathology. 2014 Jan;64(1):101-18.Stockman DL, Mod Pathol. 2014 Apr;27(4):496-501.

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.